Last reviewed · How we verify

Stendra 200 mg

VIVUS LLC · FDA-approved active Small molecule ✓ Verified May 2026 Quality 5/100

Stendra 200 mg is a Small molecule drug developed by VIVUS LLC. It is currently FDA-approved. Also known as: avanafil.

Stendra 200 mg is a small molecule medication used to treat erectile dysfunction. It is a synthetic compound, also known as avanafil or MG-S-2525, which has been studied in clinical trials for its effects on hemodynamic interactions and other conditions.

At a glance

Generic nameStendra 200 mg
Also known asavanafil
SponsorVIVUS LLC
ModalitySmall molecule
PhaseFDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Stendra 200 mg

What is Stendra 200 mg?

Stendra 200 mg is a Small molecule drug developed by VIVUS LLC.

Who makes Stendra 200 mg?

Stendra 200 mg is developed and marketed by VIVUS LLC (see full VIVUS LLC pipeline at /company/vivus-llc).

Is Stendra 200 mg also known as anything else?

Stendra 200 mg is also known as avanafil.

What development phase is Stendra 200 mg in?

Stendra 200 mg is FDA-approved (marketed).

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing